Biotaskas - Company finances
|
EUR
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|
|
Financial data
|
||||||
| Sales revenue | 9,990 | 10,360 | 4,590 | 5,090 | 1,360 | 3,675 |
| Profit before tax | 7,291 | 2,230 | 524 | 2,140 | 822 | 2,729 |
| Net profit | 6,926 | 2,118 | 498 | 2,033 | 781 | 2,565 |
| Equity | 12,297 | 14,414 | 11,913 | 9,793 | 10,574 | 6,664 |
| Liabilities | - | - | 90 | 170 | 104 | 227 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Current assets | 12,686 | 14,550 | 12,003 | 9,963 | 10,678 | 6,891 |
| Total assets | 12,686 | 14,550 | 12,003 | 9,963 | 10,678 | 6,891 |
|
Taxes paid
|
||||||
| STI taxes | - | - | - | 649 | 107 | 41 |
|
Financial indicators
|
||||||
| Revenue change y/y | - | +3.7% | -55.7% | +10.9% | -73.3% | +170.2% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 54.6% | 14.6% | 4.1% | 20.4% | 7.3% | 37.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 56.3% | 14.7% | 4.2% | 20.8% | 7.4% | 38.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 69.3% | 20.4% | 10.8% | 39.9% | 57.4% | 69.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 73.0% | 21.5% | 11.4% | 42.0% | 60.4% | 74.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Biotaskas - Social security debts
The company had no debts to Sodra
Biotaskas - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Biotaskas, MB (code 304927844) is a small partnership engaged in research and experimental development on other natural sciences and engineering. In 2025, the company generated revenue of EUR 3.7K and net profit of EUR 2.6K, with a profit margin of 69.8%. Performance improved strongly from 2024, when revenue was EUR 1.4K and net profit EUR 781, after a stronger 2023 result of EUR 5.1K revenue and EUR 2.0K net profit. Over the three-year period, revenue weakened in 2024 and then rebounded in 2025, while profitability stayed positive throughout. The latest year also shows solid balance sheet strength: total assets were EUR 6.9K, equity EUR 6.7K and liabilities EUR 227. Equity accounted for 96.7% of assets, and debt remained very low, with a debt-to-equity ratio of 0.03. Return on equity was 38.5% and return on assets 37.2%, while asset turnover stood at 0.53x. The figures indicate a very small but profitable business with limited leverage and a stable equity base in 2025.